Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 7/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | F10 | P00742 | 9/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867967 | 0.82 | OPRM1 (0.44) | GRIN2BACHE | |
| SCHEMBL5868070 | 0.82 | SIGMAR1 (0.44) | GRIN2BCYP2D6CYP2C9ACHEKDM4E | |
| SCHEMBL5868136 | 0.80 | KDM1A (0.45) | ITGB3ITGA2BTSHR | |
| SCHEMBL5868096 | 0.80 | LTA4H (0.41) | GRIN2BCYP2D6CYP2C9ACHECHRM4 | |
| SCHEMBL5867867 | 0.79 | KDM4E (0.57) | GRIN2BCYP2D6CYP2C9CYP3A4KDM4E | |
| SCHEMBL7091228 | 0.79 | F10 (0.54) | GRIN2BCYP2D6CYP2C9F10KDM4E | |
| SCHEMBL7086594 | 0.77 | KDM4E (0.65) | GRIN2BF10KDM4EALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL5868319 | 0.75 | F10 (0.53) | CYP2D6F10CYP3A4ACHEKDM4E | |
| SCHEMBL5867974 | 0.75 | CHRM4 (0.46) | ACHECHRM4 | |
| SCHEMBL5868178 | 0.73 | F10 (0.48) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259868-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1289954-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | GRIN2B 4207/4885CYP2D6 3067/4885CYP2C9 2658/4885 |
| US-20040259868-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | GRIN2B 4499/4885CYP2D6 2052/4885CYP2C9 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.